Development of the Troponin Detection System Based on the Nanostructure

Lee, Taek; Ahn, Jae-Hyuk; Choi, Jin‐Ha; Lee, Yeon-Ju; Kim, Jin-Myung; Park, Chulhwan; Jang, Hongje; Kim, Tae-Hyung

doi:10.3390/mi10030203

Cited by 22 publications

(11 citation statements)

References 101 publications

(119 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AMI is the primary reason for demise worldwide among heart-related disorders [ 112 ]. It is usually initiated by a decrease or blockage of blood flow to a section of the heart, resulting in necrosis of heart muscle [ 113 ].…”

Section: Selective Adhesion On Fet For Biosensing Applicationsmentioning

confidence: 99%

Biosensing based on field-effect transistors (FET): Recent progress and challenges

Sadighbayan

Hasanzadeh

Ghafar-Zadeh

2020

TrAC Trends in Analytical Chemistry

184

View full text Add to dashboard Cite

The use of field-Effect-Transistor (FET) type biosensing arrangements has been highlighted by researchers in the field of early biomarker detection and drug screening. Their non-metalized gate dielectrics that are exposed to an electrolyte solution cover the semiconductor material and actively transduce the biological changes on the surface. The efficiency of these novel devices in detecting different biomolecular analytes in a real-time, highly precise, specific, and label-free manner has been validated by numerous research studies. Considerable progress has been attained in designing FET devices, especially for biomedical diagnosis and cell-based assays in the past few decades. The exceptional electronic properties, compactness, and scalability of these novel tools are very desirable for designing rapid, label-free, and mass detection of biomolecules. With the incorporation of nanotechnology, the performance of biosensors based on FET boosts significantly, particularly, employment of nanomaterials such as graphene, metal nanoparticles, single and multi-walled carbon nanotubes, nanorods, and nanowires. Besides, their commercial availability, and high-quality production on a large-scale, turn them to be one of the most preferred sensing and screening platforms. This review presents the basic structural setup and working principle of different types of FET devices. We also focused on the latest progression regarding the use of FET biosensors for the recognition of viruses such as, recently emerged COVID-19, Influenza, Hepatitis B Virus, protein biomarkers, nucleic acids, bacteria, cells, and various ions. Additionally, an outline of the development of FET sensors for investigations related to drug development and the cellular investigation is also presented. Some technical strategies for enhancing the sensitivity and selectivity of detection in these devices are addressed as well. However, there are still certain challenges which are remained unaddressed concerning the performance and clinical use of transistor-based point-of-care (POC) instruments; accordingly, expectations about their future improvement for biosensing and cellular studies are argued at the end of this review.

show abstract

Section: Selective Adhesion On Fet For Biosensing Applicationsmentioning

confidence: 99%

Biosensing based on field-effect transistors (FET): Recent progress and challenges

Sadighbayan

Hasanzadeh

Ghafar-Zadeh

2020

TrAC Trends in Analytical Chemistry

184

View full text Add to dashboard Cite

show abstract

“…Biosensing methods used for the detection of cTnI and myoglobin include surface plasmon resonance [ 15 ], chemiluminescence [ 16 ], mass spectrometry [ 17 ], liquid chromatography [ 18 ], and fluorescence energy transfer [ 19 ]. Most of these methods are relatively specific and sensitive but costly and time consuming; furthermore, these methods require high-level complex instrumentation, which is not available in most healthcare settings.…”

Section: Introductionmentioning

confidence: 99%

Graphene Quantum Dots-Based Electrochemical Biosensing Platform for Early Detection of Acute Myocardial Infarction

et al. 2022

View full text Add to dashboard Cite

Heart failure resulting from acute myocardial infarction (AMI) is an important global health problem. Treatments of heart failure and AMI have improved significantly over the past two decades; however, the available diagnostic tests only give limited insights into these heterogeneous conditions at a reversible stage and are not precise enough to evaluate the status of the tissue at high risk. Innovative diagnostic tools for more accurate, more reliable, and early diagnosis of AMI are urgently needed. A promising solution is the timely identification of prognostic biomarkers, which is crucial for patients with AMI, as myocardial dysfunction and infarction lead to more severe and irreversible changes in the cardiovascular system over time. The currently available biomarkers for AMI detection include cardiac troponin I (cTnI), cardiac troponin T (cTnT), myoglobin, lactate dehydrogenase, C-reactive protein, and creatine kinase and myoglobin. Most recently, electrochemical biosensing technologies coupled with graphene quantum dots (GQDs) have emerged as a promising platform for the identification of troponin and myoglobin. The results suggest that GQDs-integrated electrochemical biosensors can provide useful prognostic information about AMI at an early, reversible, and potentially curable stage. GQDs offer several advantages over other nanomaterials that are used for the electrochemical detection of AMI such as strong interactions between cTnI and GQDs, low biomarker consumption, and reusability of the electrode; graphene-modified electrodes demonstrate excellent electrochemical responses due to the conductive nature of graphene and other features of GQDs (e.g., high specific surface area, π–π interactions with the analyte, facile electron-transfer mechanisms, size-dependent optical features, interplay between bandgap and photoluminescence, electrochemical luminescence emission capability, biocompatibility, and ease of functionalization). Other advantages include the presence of functional groups such as hydroxyl, carboxyl, carbonyl, and epoxide groups, which enhance the solubility and dispersibility of GQDs in a wide variety of solvents and biological media. In this perspective article, we consider the emerging knowledge regarding the early detection of AMI using GQDs-based electrochemical sensors and address the potential role of this sensing technology which might lead to more efficient care of patients with AMI.

show abstract

“…Damage to myocardial cell integrity is followed by partial release of cTnI into the blood, and elevated cardiac troponin concentrations in peripheral blood indicate myocardial cell damage (Palladino et al, 2018;Karimi-Maleh et al, 2020a;Çimen et al, 2020). Since myocardial infarction is one of the most important factors leading to myocardial cell destruction, monitoring of cTnI blood concentrations is particularly important for the early detection of myocardial infarction (Ye et al, 2018;Lee et al, 2019;Sun et al, 2019a;Karimi-Maleh et al, 2020b, 2021. There is evidence that even small elevations in cTnI may be associated with poor prognosis.…”

Section: Introductionmentioning

confidence: 99%

A Novel Graphene-Based Nanomaterial Modified Electrochemical Sensor for the Detection of Cardiac Troponin I

Zhang

et al. 2021

Front. Chem.

View full text Add to dashboard Cite

Acute myocardial infarction has a high clinical mortality rate. The initial exclusion or diagnosis is important for the timely treatment of patients with acute myocardial infarction. As a marker, cardiac troponin I (cTnI) has a high specificity, high sensitivity to myocardial injury and a long diagnostic window. Therefore, its diagnostic value is better than previous markers of myocardial injury. In this work, we propose a novel aptamer electrochemical sensor. This sensor consists of silver nanoparticles/MoS2/reduced graphene oxide. The combination of these three materials can provide a synergistic effect for the stable immobilization of aptamer. Our proposed aptamer electrochemical sensor can detect cTnl with high sensitivity. After optimizing the parameters, the sensor can provide linear detection of cTnl in the range of 0.3 pg/ml to 0.2 ng/ml. In addition, the sensor is resistant to multiple interferents including urea, glucose, myoglobin, dopamine and hemoglobin.

show abstract

Development of the Troponin Detection System Based on the Nanostructure

Cited by 22 publications

References 101 publications

Biosensing based on field-effect transistors (FET): Recent progress and challenges

Biosensing based on field-effect transistors (FET): Recent progress and challenges

Graphene Quantum Dots-Based Electrochemical Biosensing Platform for Early Detection of Acute Myocardial Infarction

A Novel Graphene-Based Nanomaterial Modified Electrochemical Sensor for the Detection of Cardiac Troponin I

Contact Info

Product

Resources

About